Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.

Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, Mohamed AA, Mohamedelamin ESW, Bahar MEN, Attalla HY, Siddig EE, Mhmoud NA, Musa AM, van de Sande WWJ, Scherrer B, Oyieko P, Egondi TW, Onyango KO, Hata K, Chu WY, Dorlo TPC, Brüggemann RJ, Nyaoke BA, Strub-Wourgaft N, Zijlstra EE

Open source

DOI: 10.1016/s1473-3099(24)00404-3
Published: 2024 Nov
Container: The Lancet. Infectious diseases
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-24-00404-3,
  title = {Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.},
  author = {Fahal AH and Ahmed ES and Bakhiet SM and Bakhiet OE and Fahal LA and Mohamed AA and Mohamedelamin ESW and Bahar MEN and Attalla HY and Siddig EE and Mhmoud NA and Musa AM and van de Sande WWJ and Scherrer B and Oyieko P and Egondi TW and Onyango KO and Hata K and Chu WY and Dorlo TPC and Brüggemann RJ and Nyaoke BA and Strub-Wourgaft N and Zijlstra EE},
  year = {2024},
  journal = {The Lancet. Infectious diseases},
  doi = {10.1016/s1473-3099(24)00404-3},
  url = {https://doi.org/10.1016/s1473-3099(24)00404-3}
}

RIS

TY  - JOUR
TI  - Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.
AU  - Fahal AH
AU  - Ahmed ES
AU  - Bakhiet SM
AU  - Bakhiet OE
AU  - Fahal LA
AU  - Mohamed AA
AU  - Mohamedelamin ESW
AU  - Bahar MEN
AU  - Attalla HY
AU  - Siddig EE
AU  - Mhmoud NA
AU  - Musa AM
AU  - van de Sande WWJ
AU  - Scherrer B
AU  - Oyieko P
AU  - Egondi TW
AU  - Onyango KO
AU  - Hata K
AU  - Chu WY
AU  - Dorlo TPC
AU  - Brüggemann RJ
AU  - Nyaoke BA
AU  - Strub-Wourgaft N
AU  - Zijlstra EE
PY  - 2024
JO  - The Lancet. Infectious diseases
DO  - 10.1016/s1473-3099(24)00404-3
UR  - https://doi.org/10.1016/s1473-3099(24)00404-3
ER  -

APA

AH, F., ES, A., SM, B., OE, B., LA, F., AA, M., ESW, M., MEN, B., HY, A., EE, S., NA, M., AM, M., WWJ, V. D. S., B, S., P, O., TW, E., KO, O., K, H., WY, C., TPC, D., RJ, B., BA, N., N, S., & EE, Z. (2024). Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial.. The Lancet. Infectious diseases. https://doi.org/10.1016/s1473-3099(24)00404-3

Source records

pubmed · retrieved 2026-09-27T12:48:29.172Z